Sandra Tuyaerts

Vrije Universiteit Brussel

Belgium

Research Interests

Explore related searches

Professors in Belgium Professors in Immunology Immunology professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (22)

Inès Dufait

Vrije Universiteit Brussel

BELGIUM

View details

Katty Zeven

Vrije Universiteit Brussel

BELGIUM

View details

Yannick De Vlaeminck

Vrije Universiteit Brussel

BELGIUM

View details

JENS TIJTGAT

Vrije Universiteit Brussel

BELGIUM

View details

Lorenzo Franceschini

Vrije Universiteit Brussel

BELGIUM

View details

Manon Vounckx

Vrije Universiteit Brussel

BELGIUM

View details

Wietse Geens

Vrije Universiteit Brussel

BELGIUM

View details

Jolien De Munck

Vrije Universiteit Brussel

BELGIUM

View details

Joeri Aerts

Prof. at Vrije Universiteit Brussel (VUB)

Vrije Universiteit Brussel (VUB)

BELGIUM

View details

Ann De Becker

Vrije Universiteit Brussel

BELGIUM

View details

Stefan Naulaerts

Katholieke Universiteit Leuven

BELGIUM

View details

Xenia Geeraerts

Vrije Universiteit Brussel

BELGIUM

View details

Bart Ilsen

Vrije Universiteit Brussel

BELGIUM

View details

Ramses Forsyth

Vrije Universiteit Brussel

BELGIUM

View details

Kiavash Movahedi

Vrije Universiteit Brussel

BELGIUM

View details

Alex De Caluwe

Université libre de Bruxelles (ULB)

BELGIUM

View details

Anne-Marie Vanbinst

Vrije Universiteit Brussel

BELGIUM

View details

Karolien Vekens

Vrije Universiteit Brussel

BELGIUM

View details

Jannie Borst

Leiden University Medical Center

NETHERLANDS

View details

Yanling Xiao

Assistant Professor

Leiden University Medical Center

NETHERLANDS

View details

Bart Neyns

Vrije Universiteit Brussel

BELGIUM

View details

Ben Caljon

Vrije Universiteit Brussel

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sandra Tuyaerts

Research Interests

Explore related searches

Contact this professor

Articles (18)

Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells in vitro and induces immunogenic cell death

A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6<sup>high</sup> uterine leiomyosarcoma to PD‐1 blockade

Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity

Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab

Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives

Current "state of the art" on dendritic cell-based cancer vaccines in melanoma

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma

Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.

Trial watch

159P Pembrolizumab, SBRT, and immunomodulation for recurrent and/or refractory cervical or endometrial carcinoma

INTRA-CRANIAL ADMINISTRATION OF CTLA-4 AND PD-1 IMMUNE CHECKPOINT-INHIBITING MONOCLONAL ANTIBODIES IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTI-COHORT ADAPTIVE PHASE I CLINICAL TRIAL

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells

Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?

Collaborators (22)

Inès Dufait

Katty Zeven

Yannick De Vlaeminck

JENS TIJTGAT

Lorenzo Franceschini

Manon Vounckx

Wietse Geens

Jolien De Munck

Joeri Aerts

Ann De Becker

Stefan Naulaerts

Xenia Geeraerts

Bart Ilsen

Ramses Forsyth

Kiavash Movahedi

Alex De Caluwe

Anne-Marie Vanbinst

Karolien Vekens

Jannie Borst

Yanling Xiao

Bart Neyns

Ben Caljon

Make your next move.